If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Adapting to a new normal

C&EN advice columnist offers 4 tips on adapting to times of uncertainty

image name

Farms lead to gut bugs swapping

Bacteria with antimicrobial-resistance genes pass from livestock to farm interns

Shortage of RNA extraction kits hampers efforts to ramp up COVID-19 testing

Qiagen vows to ramp up production of kits as scientists turn to social media to plea for donations

image name
Research Funding

US stimulus bill includes funding for coronavirus research

The National Institutes of Health receives the vast majority of the support

What can initial remdesivir data tell us about tackling COVID-19?

Gilead Sciences’ antiviral is in multiple late-stage trials to treat coronavirus infections. Don’t expect a home run, say infectious disease experts